CorMedix Inc. (CRMD) Stock: What Does the Chart Say Tuesday?

The market has been high on CorMedix Inc. (CRMD) stock recently. CRMD gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

CorMedix Inc. has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on CRMD!

See Full CRMD Report

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With CRMD Stock Today?

CorMedix Inc. (CRMD) stock is trading at $3.43 as of 12:11 PM on Tuesday, Oct 31, a rise of $0.23, or 7.37% from the previous closing price of $3.19. The stock has traded between $3.22 and $3.46 so far today. Volume today is light. So far 282,015 shares have traded compared to average volume of 428,484 shares. To screen for more stocks like CorMedix Inc. click here.

More About CorMedix Inc.

Cormedix Inc is a biopharmaceutical company that focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. It has been in-licensed to develop and commercialize Neutrolin, which is a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings such as hemodialysis, total parenteral nutrition, and oncology. The Neutrolin product is designed to target unmet medical needs. Click Here to get the full Stock Report for CorMedix Inc. stock.